# Hipro Biotechnology Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/hipro-biotechnology-co

- Industry: Medical Devices & Equipment
- Headquarters: Shijiazhuang, China
- Website: www.hiprochina.com
- Total disclosed funding: $15M
- Latest round: Series C (Dec 19, 2020)
- Investors on record: 3

## About

Based in Shijiazhuang, China and established in 2006, Hipro Biotechnology Co.,Ltd is a healthcare company that provides in vitro diagnosis equipment and diagnostic reagent. The company is headquartered in Shijiazhuang, Hebei Province, with wholly owned subsidiaries in Silicon Valley, USA and Freiburg, Germany as reagent R&D and process R&D centers. The company has set up subsidiaries in Taizhou, Jiangsu Province and Nanshan District, Shenzhen for new industrial bases and R&D centers. Its headquarter base is self-built with more than 8,000 square meters of garden-style plant, with GMP standardized production plant, and the company has passed TUV Rheinland ISO13485 system certification. At present, the company has built 15 fully automated assembly lines, which can realize a daily production capacity of 150,000 reagents.

The company is engaged in the research and development, manufacture and sale of instruments and reagents for prompt oncetesting (POC) in the clinical in vitro diagnostics industry and related services. It has developed its own integrated sampler platform products such as A1-PLUS, a fully automated immunoassay analyzer, a scattering turbidimetric immunoassay analyzer, and an ecological platform for laboratory automation.

## Funding rounds

- Series C, Dec 19, 2020, $15M — China Merchants Capital
- Series B, Dec 5, 2018 — Oriental Fortune Capital
- Angel, Jan 1, 2010 — MPC

## Investors

- MPC — Angel
- Oriental Fortune Capital (https://capitalatlas.ai/funds/oriental-fortune-capital) — Series B
- China Merchants Capital (https://capitalatlas.ai/funds/china-merchants-capital) — Series C